Published on 02/12/2025

Defending AET/DBT Choices Under Scrutiny

Extractables and leachables (E&L) testing is critical for ensuring the safety and efficacy of pharmaceutical products. As regulatory scrutiny increases, professionals in the pharmaceutical and biopharmaceutical industries must not only understand the concepts of Analytical Evaluation Threshold (AET) and Dose-Based Threshold (DBT) but also how to defend these choices against regulatory scrutiny. This comprehensive guide will walk you through the necessary steps to effectively navigate the complexities of E&L risk assessments, AET/DBT calculations, and container closure integrity (CCI) evaluations while adhering to stringent US FDA, EMA, and MHRA expectations.

Understanding Extractables and Leachables: Definitions and Importance

The terms extractables and leachables refer to substances that may migrate from packaging materials into medication. Extractables are compounds that can be extracted from packaging materials under specific laboratory conditions—typically involving the use of solvents and heat or pressure. Leachables, on the other hand, are the chemical entities that migrate from the packaging into the drug product during storage or use.

Understanding E&L is essential for several reasons:

• Patient Safety: Direct contact with leachables can pose a risk to patient safety, influencing physiological responses and leading to adverse reactions.
• Efficacy: The efficacy of a pharmaceutical product can be compromised if leachables interact negatively with the active pharmaceutical ingredients (APIs).
• Regulatory Compliance: Regulatory agencies including the FDA and EMA require comprehensive E&L assessments to ensure compliance with cGMP and EU GMP Annex 1.
• Market Approval: Robust E&L studies and justifications for AET/DBT are necessary for regulatory filings to gain market approval.

This understanding lays the foundation for effective E&L testing, AET/DBT justifications, and successfully navigating inspection readiness.

Step 1: Conducting an E&L Risk Assessment

The first step in defending AET and DBT choices involves conducting a comprehensive E&L risk assessment. This assessment should encompass all materials that come in contact with the product, including single-use systems.

A well-structured E&L risk assessment includes the following components:

• Material Characterization: Identify and characterize materials used in the packaging and delivery systems. Perform a thorough evaluation to ascertain their chemical composition and any potential for extracting or leaking harmful substances.
• Intended Use Evaluation: Understand the intended use conditions of the packaging materials, including temperature fluctuations, storage duration, and the nature of the drug product.
• Previous Data Utilization: Review available data on similar materials and previous E&L testing results. Use historical data to support the risk assessment.
• Identification of Potential Risks: Rank the identified materials for potential risk regarding extractables and leachables, emphasizing those that have documented migration issues.

Assembling a multidisciplinary team that includes chemists, analysts, and regulatory affairs professionals can enhance the rigor of the assessment.

Step 2: Performing AET and DBT Calculations

Once a robust risk assessment is concluded, the next step involves valid AET and DBT calculations. These calculations serve as the benchmark for evaluating E&L results against safety thresholds.

Understanding the Concepts

The Analytical Evaluation Threshold (AET) establishes the lowest concentration of leachables that requires evaluation due to potential risk to patient safety, while the Dose-Based Threshold (DBT) is determined based on the ratio of the total daily dose of a drug to the estimated daily concentration of leachables that could be present in the product.

Performing the Calculations

The following steps should be observed when calculating AET and DBT:

• AET Calculation: Use toxicological data to determine the toxicological threshold of concern (TTC) for each leachable. AET can be derived by dividing this TTC by an appropriate safety factor.
• DBT Calculation: DBT is calculated by considering the maximum daily dosage of the drug. The formula is:

DBT = (Maximum Daily Dose / Body Weight) x (Toxicological Threshold)

Once the calculations are completed, the results should be meticulously documented, providing a clear rationale for chosen values and thresholds.

Step 3: Designing an Appropriate Testing Strategy

Upon establishing AET and DBT, the next step is to design a comprehensive testing strategy geared toward achieving compliance with regulatory expectations while ensuring product safety.

Components of the Testing Strategy

• Selection of Test Conditions: Define realistic storage and extraction conditions that reflect actual use scenarios. Mimic conditions like temperature, time, and solvent contact as per relevant guidance such as USP USP Container Closure Integrity (CCI) guidelines.
• Analytical Method Validation: Ensure that the analytical methods used for detection of E&L are validated for specificity, sensitivity, and reproducibility. Adoption of standardized methodologies is also crucial.
• Sampling Strategy: Create a robust sampling strategy that includes replicates and controls, which allow for consistent and comparable results.
• Documentation: Maintain rigorous documentation from testing preparations through final reports to ensure transparency in the testing processes and results.

Compliance and Regulatory Considerations

The EU GMP Annex 1 and guidelines from the Product Quality Research Institute (PQRI) should be diligently examined to ensure that your testing strategy aligns with regulatory expectations.

Step 4: Evaluating Container Closure Integrity (CCI)

Container closure integrity assessment is a pivotal element of validating single-use systems. Poor integrity can lead to microbial contamination and loss of product efficacy. There are several methods to evaluate CCI, including:

• Visual Inspection: Look for visible defects on the primary packaging components.
• Leak Testing: Utilize methods such as dye penetration, vacuum decay, or pressure decay tests to demonstrate the integrity of the closure system.
• Microbial Challenge Studies: These assess how effectively the closure system protects the product from contamination.

Best Practices for CCI Testing

When evaluating CCI, be sure to implement best practices that include:

• Contextual Evaluation: Test in conditions reflecting real-world storage and handling to ensure reliability.
• Materials Compatibility: Always consider the materials used in packaging that can potentially affect integrity over the shelf-life of the product.

Step 5: Continual Monitoring and Updates to E&L Assessments

Once AET/DBT choices and CCI practices are established and documented, they must be reconsidered periodically. Continuous monitoring, re-evaluation of risk assessments, and updates to testing strategies may be warranted based on new findings or changes in regulatory standards.

Periodic Reassessment

• Trends Analysis: Conduct a regular review of data collected from testing and any reported adverse events to identify trends.
• Regulatory Updates: Stay current with regulatory updates from agencies such as EMA and the MHRA to ensure ongoing compliance.

Collaboration with Cross-Functional Teams

Involve cross-functional teams in continuous risk assessment efforts. Collaborating with Quality Assurance, Research & Development, and Production departments can enhance the overall robustness of the E&L risk management program.

Final Thoughts: Building Defensible AET/DBT Strategies

Defending analytical evaluation threshold (AET) and dose-based threshold (DBT) choices involves a thorough understanding of extractables and leachables, adherence to regulatory guidelines, and meticulous documentation of methodologies and results. A well-rounded approach incorporating risk assessment, comprehensive calculations, effective testing, and ongoing monitoring is crucial for ensuring patient safety and regulatory compliance.

By following the structured steps outlined in this article, professionals can effectively navigate the complexities of E&L and container closure integrity challenges while fostering a culture of rigorous compliance within their organizations. This solid foundation will not only defend against scrutiny but also enhance the overall quality of pharmaceutical products in the market.